175 related articles for article (PubMed ID: 24964358)
1. Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir.
Blanco JL; Gonzalez-Cordón A; Llibre JM; Calvo M; Gutierrez F; Podzamczer D; Laguno M; Fumero E; Murillas J; Mallolas J; Martinez-Rebollar M; Lonca M; Perez I; Gatell JM; Martinez E
Antivir Ther; 2015; 20(5):487-92. PubMed ID: 24964358
[TBL] [Abstract][Full Text] [Related]
2. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
[No Abstract] [Full Text] [Related]
3. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
4. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
5. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.
van Lunzen J; Pozniak A; Gatell JM; Antinori A; Klauck I; Serrano O; Baakili A; Osiyemi O; Sevinsky H; Girard PM
J Acquir Immune Defic Syndr; 2016 Apr; 71(5):538-43. PubMed ID: 26605505
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA
PLoS One; 2015; 10(2):e0118228. PubMed ID: 25723472
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.
Jaeckle M; Khaykin P; Haberl A; De Leuw P; Schüttfort G; Stephan C; Wolf T
Int J STD AIDS; 2016 Nov; 27(13):1170-1179. PubMed ID: 26429890
[TBL] [Abstract][Full Text] [Related]
10. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.
López-Cortés LF; Castaño MA; López-Ruz MA; Rios-Villegas MJ; Hernández-Quero J; Merino D; Jiménez-Aguilar P; Marquez-Solero M; Terrón-Pernía A; Tellez-Pérez F; Viciana P; Orihuela-Cañadas F; Palacios-Baena Z; Vinuesa-Garcia D; Fajardo-Pico JM; Romero-Palacios A; Ojeda-Burgos G; Pasquau-Liaño J
PLoS One; 2016; 11(2):e0148924. PubMed ID: 26872331
[TBL] [Abstract][Full Text] [Related]
12. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.
Caby F; Schneider L; Blanc C; Soulié C; Tindel M; Peytavin G; Agher R; Valantin MA; Tubiana R; Wirden M; Calvez V; Marcelin AG; Katlama C
Infection; 2014 Apr; 42(2):295-301. PubMed ID: 24155032
[TBL] [Abstract][Full Text] [Related]
14. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
[TBL] [Abstract][Full Text] [Related]
16. Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4).
Potard V; Simon A; Lacombe JM; Parienti JJ; Costagliola D;
Clin Infect Dis; 2016 Nov; 63(9):1254-1261. PubMed ID: 27543648
[TBL] [Abstract][Full Text] [Related]
17. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
[TBL] [Abstract][Full Text] [Related]
18. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD
AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.
Rusconi S; Vitiello P; Adorni F; Bruzzone B; De Luca A; Micheli V; Meraviglia P; Maserati R; Di Pietro M; Colao G; Penco G; Di Biagio A; Punzi G; Monno L; Zazzi M;
Clin Microbiol Infect; 2013 Oct; 19(10):936-42. PubMed ID: 23289841
[TBL] [Abstract][Full Text] [Related]
20. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.
Masiá M; Martínez E; Padilla S; Gatell JM; Gutiérrez F
J Antimicrob Chemother; 2013 Feb; 68(2):409-13. PubMed ID: 23075691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
